

Product Data Sheet

Product Name: Stauprimide

Cat. No.: GC17839

Chemical Properties

Cas. No. 154589-96-5

Chemical Name N-((5S,6S,7R,9S)-6-methoxy-5-methyl-14,16-dioxo-5,6,7,8,9,14,15,16-octahydro-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-7-yl)-N-methylbenzamide

SMILES O=C(C1=C2C3=C(C4=C15)N(C6=CC=CC=C46)[C@H]7O[C@]([C@H]([C@@H](C7)N(C(C8=CC=CC=C8)=O)C)OC)(C)N3C9=CC=CC=C29)NC5=O

Formula C₃₅H₂₈N₄O₅ M.Wt 584.62

Solubility DMF: 25 mg/ml, DMF:PBS(pH7.2) (1:2): 0.3 mg/ml, DMSO: 10 mg/ml, Ethanol: 0.2 mg/ml
Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Background

Stauprimide is a staurosporine analog that promotes embryonic stem cell (ESC) differentiation. Stauprimide is a non-broad spectrum inhibitor that binds to the MYC transcription factor NME2 and blocks its nuclear localization in ESCs, which results in down-regulation of MYC transcription[1].

Stauprimide (10 μM; 6 hours) suppresses MYC transcription in the majority of cell lines tested with an EC₅₀ range of 30 nM-8 μM, and decreases MYC levels between 15% to over 90%[1]. Stauprimide (2-8 μM; 24-72 hours) down-regulates MYC leads to the inhibition of cell proliferation in vitro with an IC₅₀ of 780 nM in RXF 393 cells[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Stauprimide (5 μ M; 3 hours) suppresses MYC Transcription by decreasing NME2 Nuclear Translocation[1]. Stauprimide (4-10 μ M; 6 hours) acts with different EC50s and with different degrees of maximal MYC mRNA down-regulation in different cell lines[1].

Stauprimide (oral administration; 50 mg/kg; once daily; 30 days, 55 days) blocks tumor growth, reduces MYC protein levels in xenograft mouse with RXF 393 or CAKI-1 cells and inhibits MYC transcription in the RXF 393 tumor[1].

References:

[1]. Bouvard C, et al. Small molecule selectively suppresses MYC transcription in cancer cells. Proc Natl Acad Sci USA. 2017 Mar 28;114(13):3497-3502.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA